OBJECTIVE: To study effect of overexpression of @entity519 -inducible factor-1a induced by @entity871 in  vivo in LNCaP @entity5 on @entity5 growth rate. METHODS: The @entity263 LNCaP cells were inoculated in the abdomen of @entity19 . All the @entity19 were randomly placed in the gas chamber with different @entity26 content. The groups were divided as follows: twelve @entity19 in @entity519 group, sixteen @entity19 in normoxia group, ten @entity19 in @entity871 group. After 28  d of treatment, the @entity19 were weighed, the blood samples were taken from the left ventricle, and the @entity5 was isolated and weighed. @entity5 growth, @entity7499 and vascularization, @entity1965 expression and intracellular signal transduction molecules expression in each group of xenografts were detected and analyzed by using Western blotting and immunofluorescence and determination of hemoglobin. RESULTS: Comparison of the growth of xenografts in each group showed that, the xenografts growth of @entity519 group was more quickly than that of normoxia group. The difference was statistically significant (P  =  0.004). The difference in xenografts growth between @entity871 group compared and normoxia group was not statistically significant (P  >  0.05). The expressions of @entity1965 , @entity1611 and @entity1611 -R of xenografts in @entity871 group were significantly higher than those of normoxia group (P  <  0.05). The expression of @entity1965 of xenografts in @entity519 group and normoxia group were similar. The blood growth rate of xenografts in @entity519 group (170%) was significantly higher than that of normoxia group (40%) (P  <  0.05). The expression of @entity10182 of xenografts in @entity871 group was significantly higher than that of normoxia group (P  <  0.05). CONCLUSIONS: When @entity871 induces the overexpression of @entity1965 in LNCaP @entity5 , it will not affect @entity5 growth. It provides a new ideas and theoretical basis for the clinical treatment of @entity263 .

Effect of overexpression of XXXX -inducible factor-1a induced by @entity871 in  vivo in LNCaP @entity5 on @entity5 growth rate.

@entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity7499 :: ('MESH:D016510', 'Disease') :: ['angiogenesis'] @entity10182 :: ('18024(Tax:10090)', 'Gene') :: ['Nrf2'] @entity871 :: ('MESH:D018496', 'Disease') :: ['hyperoxia'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia'] @entity1965 :: ('15251(Tax:10090)', 'Gene') :: ['HIF-1a'] @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['VEGF']
@entity519 :: (MESH:D000860,Disease) :: ['hypoxia']
